Testing MSA-01 for multiple system atrophy
Part of Brain & nervous system clinical trials.
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MSA that is 'clinically established' or 'clinically probable' using standard criteria.
- You can walk on your own or with a walker or cane.
- You are able to come to the study center for appointments.
- You are willing to stop taking CoQ10 supplements during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new experimental medicine called SST001 in people with Parkinson's disease (PD) and multiple system atrophy (MSA), as well as healthy volunteers. The study checks whether SST001 is safe, how the body processes it, and where it goes in the body using imaging scans.
This study involves people with possible or probable multiple system atrophy (MSA) joining a specialized clinic team and attending visits every 4 months. It’s meant to improve care planning and support by bringing different specialists together.
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
Hear when a new Multiple System Atrophy (MSA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.